Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry.

Viktorin-Baier P, Putora PM, Schmid HP, Plasswilm L, Schwab C, Thoeni A, Hochreiter W, Prikler L, Suter S, Stucki P, Müntener M, Blick N, Schiefer H, Güsewell S, Zürn K, Engeler D.

BJU Int. 2020 Jan 21. doi: 10.1111/bju.15003. [Epub ahead of print]

PMID:
31965694
2.

Erratum: Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi.

Fankhauser CD, Hermanns T, Lieger L, Diethelm O, Umbehr M, Luginbühl T, Sulser T, Müntener M, Poyet C.

Clin Kidney J. 2018 Apr 18;12(2):309-310. doi: 10.1093/ckj/sfy030. eCollection 2019 Apr.

3.

Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi.

Fankhauser CD, Hermanns T, Lieger L, Diethelm O, Umbehr M, Luginbühl T, Sulser T, Müntener M, Poyet C.

Clin Kidney J. 2018 Jun;11(3):364-369. doi: 10.1093/ckj/sfx151. Epub 2018 Jan 25. Erratum in: Clin Kidney J. 2018 Apr 18;12(2):309-310.

4.

[Evaluation of a prostate cancer E‑health tutorial : Development and testing of the website prostata-information.ch].

Schaffert R, Dahinden U, Hess T, Bänziger A, Kuntschik P, Odoni F, Spörri P, Strebel RT, Kamradt J, Tenti G, Mattei A, Müntener M, Subotic S, Schmid HP, Rüesch P.

Urologe A. 2018 Feb;57(2):164-171. doi: 10.1007/s00120-017-0552-8. German.

PMID:
29209755
5.

Prevalence and causes of abnormal PSA recovery.

Lautenbach N, Müntener M, Zanoni P, Saleh L, Saba K, Umbehr M, Velagapudi S, Hof D, Sulser T, Wild PJ, von Eckardstein A, Poyet C.

Clin Chem Lab Med. 2018 Jan 26;56(2):341-349. doi: 10.1515/cclm-2017-0246.

6.

Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer.

Rupp NJ, Schüffler PJ, Zhong Q, Falkner F, Rechsteiner M, Rüschoff JH, Fankhauser C, Drach M, Largo R, Tremp M, Poyet C, Sulser T, Kristiansen G, Moch H, Buhmann J, Müntener M, Wild PJ.

J Pathol Inform. 2016 Jan 29;7:3. doi: 10.4103/2153-3539.175376. eCollection 2016.

7.

Influence of Varying Assessment Parameters on the Diagnostic Accuracy of Magnetic Resonance Imaging in the Local Staging of Prostate Cancer.

Umbehr MH, Lüscher M, Hunziker R, Falkner F, Wild PJ, Poyet C, Seifert B, Müntener M.

Urol Int. 2016;96(3):309-14. doi: 10.1159/000441733. Epub 2015 Dec 16.

8.

Bilaterally positive biopsy cores are associated with non-organ-confined disease in prostate cancer patients eligible for active surveillance.

Umbehr MH, Largo RA, Gfeller S, Tremp M, Poyet C, Paul M, Sulser T, Müntener M.

Urol Int. 2014;93(2):176-81. doi: 10.1159/000357121. Epub 2014 Mar 15.

9.

Ablative efficiency of 532-nm laser vaporization compared to transurethral resection of the prostate: results from a prospective three-dimensional ultrasound volumetry study.

Hermanns T, Gross O, Kranzbühler B, Hefermehl LJ, Poyet C, Müller A, Yap SA, Michel MS, Eberli D, Müntener M, Zimmermann M, Sulser T, Seifert HH.

World J Urol. 2014 Oct;32(5):1267-74. doi: 10.1007/s00345-013-1203-3. Epub 2013 Oct 31.

PMID:
24173627
10.

Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial.

Stenner-Liewen F, Liewen H, Cathomas R, Renner C, Petrausch U, Sulser T, Spanaus K, Seifert HH, Strebel RT, Knuth A, Samaras P, Müntener M.

J Cancer. 2013 Aug 29;4(7):597-605. doi: 10.7150/jca.7123. eCollection 2013.

11.

The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis.

Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM.

Eur Urol. 2013 Jul;64(1):106-17. doi: 10.1016/j.eururo.2013.04.019. Epub 2013 Apr 19. Review.

PMID:
23628493
12.

Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression.

Montani M, Hermanns T, Müntener M, Wild P, Sulser T, Kristiansen G.

Virchows Arch. 2013 Apr;462(4):437-43. doi: 10.1007/s00428-013-1390-8. Epub 2013 Mar 16. Erratum in: Virchows Arch. 2013 Jul;463(1):99. Herrmanns, Thomas [corrected to Hermanns, Thomas].

PMID:
23503867
13.

Artificial prostate-specific antigen persistence after radical prostatectomy.

Poyet C, Hof D, Sulser T, Müntener M.

J Clin Oncol. 2012 Feb 10;30(5):e62-3. doi: 10.1200/JCO.2011.38.2788. Epub 2011 Dec 27. No abstract available.

PMID:
22203757
14.

FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.

Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, Müntener M, Kristiansen G.

Am J Pathol. 2012 Feb;180(2):848-61. doi: 10.1016/j.ajpath.2011.10.021. Epub 2011 Dec 2.

PMID:
22138582
15.

Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates.

Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, Müntener M, Kristiansen G.

Prostate. 2012 Feb;72(3):318-25. doi: 10.1002/pros.21434. Epub 2011 Jul 7.

PMID:
21739464
16.

Lithium triborate laser vaporization of the prostate using the 120 W, high performance system laser: high performance all the way?

Hermanns T, Strebel DD, Hefermehl LJ, Gross O, Mortezavi A, Müller A, Eberli D, Müntener M, Michel MS, Meier AH, Sulser T, Seifert HH.

J Urol. 2011 Jun;185(6):2241-7. doi: 10.1016/j.juro.2011.02.023. Epub 2011 Apr 17.

17.

The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro.

Gerhardt J, Steinbrech C, Büchi O, Behnke S, Bohnert A, Fritzsche F, Liewen H, Stenner F, Wild P, Hermanns T, Müntener M, Dietel M, Jung K, Stephan C, Kristiansen G.

Am J Pathol. 2011 Apr;178(4):1847-60. doi: 10.1016/j.ajpath.2010.12.046.

18.

Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.

Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, Hermanns T, Seifert H, Müntener M, Provenzano M, Sulser T, Behnke S, Gerhardt J, Mortezavi A, Wild P, Hofstädter F, Burger M, Moch H, Kristiansen G.

BMC Cancer. 2010 Jun 30;10:341. doi: 10.1186/1471-2407-10-341.

19.

Lowering the PSA threshold for prostate biopsy from 4 to 2.5 ng/ml: influence on cancer characteristics and number of men needed to biopt.

Müntener M, Kunz U, Eichler K, Puhan M, Schmid DM, Sulser T, Strebel RT.

Urol Int. 2010;84(2):141-6. doi: 10.1159/000277589. Epub 2010 Mar 4.

20.

[Urological treatment of renal calculi].

Bolleter R, Sulser T, Müntener M.

Praxis (Bern 1994). 2009 Dec 16;98(25):1517-23. doi: 10.1024/1661-8157.98.25.1517. Review. German.

PMID:
20013688
21.

In vivo identification of uric acid stones with dual-energy CT: diagnostic performance evaluation in patients.

Stolzmann P, Kozomara M, Chuck N, Müntener M, Leschka S, Scheffel H, Alkadhi H.

Abdom Imaging. 2010 Oct;35(5):629-35. doi: 10.1007/s00261-009-9569-9. Epub 2009 Sep 2.

PMID:
19727931
22.

Robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate cancer: surgical technique and experience with the first 99 cases.

Feicke A, Baumgartner M, Talimi S, Schmid DM, Seifert HH, Müntener M, Fatzer M, Sulser T, Strebel RT.

Eur Urol. 2009 Apr;55(4):876-83. doi: 10.1016/j.eururo.2008.12.006. Epub 2008 Dec 13.

23.

Intraoperative complications of laparoscopic adrenalectomy.

Strebel RT, Müntener M, Sulser T.

World J Urol. 2008 Dec;26(6):555-60. doi: 10.1007/s00345-008-0272-1. Epub 2008 May 15. Review.

24.

Transperineal prostate intervention: robot for fully automated MR imaging--system description and proof of principle in a canine model.

Muntener M, Patriciu A, Petrisor D, Schär M, Ursu D, Song DY, Stoianovici D.

Radiology. 2008 May;247(2):543-9. doi: 10.1148/radiol.2472070737.

25.

Laparoscopic partial nephrectomy in obese and non-obese patients: comparison with open surgery.

Romero FR, Rais-Bahrami S, Muntener M, Brito FA, Jarrett TW, Kavoussi LR.

Urology. 2008 May;71(5):806-9. doi: 10.1016/j.urology.2007.11.047. Epub 2008 Feb 21.

PMID:
18291514
26.

Incidence of local recurrence and port site metastasis after laparoscopic radical nephroureterectomy.

Muntener M, Schaeffer EM, Romero FR, Nielsen ME, Allaf ME, Brito FA, Pavlovich CP, Kavoussi LR, Jarrett TW.

Urology. 2007 Nov;70(5):864-8.

PMID:
18068440
27.

Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy.

Müntener M, Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, Walsh PC, Partin AW, Nielsen ME.

Eur Urol. 2008 Apr;53(4):767-75; discussion 775-6. Epub 2007 Nov 20.

PMID:
18060681
28.

Oncologic outcomes of extravesical stapling of distal ureter in laparoscopic nephroureterectomy.

Romero FR, Schaeffer EM, Muntener M, Trock B, Kavoussi LR, Jarrett TW.

J Endourol. 2007 Sep;21(9):1025-7.

PMID:
17941780
29.

Laparoscopic treatment of simultaneous tumors in the liver and kidney.

Romero FR, Wagner AA, Bagga HS, Muntener M, Brito FA, Kavoussi LR.

Urol Int. 2007;79(2):142-4.

PMID:
17851284
30.

"MRI Stealth" robot for prostate interventions.

Stoianovici D, Song D, Petrisor D, Ursu D, Mazilu D, Muntener M, Schar M, Patriciu A.

Minim Invasive Ther Allied Technol. 2007;16(4):241-8. Erratum in: Minim Invasive Ther Allied Technol. 2007;16(6):370. Mutener, Michael [corrected to Muntener, Michael].

31.

Automatic brachytherapy seed placement under MRI guidance.

Patriciu A, Petrisor D, Muntener M, Mazilu D, Schär M, Stoianovici D.

IEEE Trans Biomed Eng. 2007 Aug;54(8):1499-506.

32.

A randomised controlled trial of post-operative rehabilitation after surgical decompression of the lumbar spine.

Mannion AF, Denzler R, Dvorak J, Müntener M, Grob D.

Eur Spine J. 2007 Aug;16(8):1101-17. Epub 2007 Jun 26.

33.

Laparoscopic heminephrectomy for renal cell carcinoma in cross-fused ectopic kidney.

Romero FR, Chan DY, Muntener M, Bagga HS, Brito FA, Kavoussi LR.

Urology. 2007 Apr;69(4):779.e11-3.

PMID:
17445678
34.

Hemothorax after percutaneous cryoablation of the kidney: part 2.

Romero FR, Muntener M, Sulman A, Brito FA, Kavoussi LR.

Eur Urol. 2007 Apr;51(4):1134-5. No abstract available.

PMID:
17415915
35.

Metastatic primitive neuroectodermal tumor to the kidney.

Romero FR, Rais-Bahrami S, Muntener M, Permpongkosol S, Fine SW, Paidas CN, Jarrett TW.

Urol Int. 2007;78(3):286-8.

PMID:
17406144
36.

Rebuttal from authors re: Peter Albers. Quality criteria of laparoscopic nephroureterectomy. Eur Urol. 2007;51:1481-2.

Muntener M, Schaeffer EM, Nielsen ME, Romero FR, Allaf ME, Brito FA, Pavlovich CP, Kavoussi LR, Jarrett TW.

Eur Urol. 2007 Jun;51(6):1482-4. Epub 2007 Feb 20. No abstract available.

PMID:
17335960
37.

Total laparoscopic gastrocystoplasty: experimental technique in a porcine model.

Romero FR, Trapp C, Muntener M, Brito FA, Kavoussi LR, Jarrett TW.

Int Braz J Urol. 2007 Jan-Feb;33(1):94-9; discussion 99.

38.

Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome.

Muntener M, Aellig S, Kuettel R, Gehrlach C, Sulser T, Strebel RT.

Eur Urol. 2007 Aug;52(2):510-5. Epub 2007 Feb 5. Erratum in: Eur Urol. 2008 Feb;53(2):456.

PMID:
17306446
39.

Long-term oncologic outcome after laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma.

Muntener M, Nielsen ME, Romero FR, Schaeffer EM, Allaf ME, Brito FA, Pavlovich CP, Kavoussi LR, Jarrett TW.

Eur Urol. 2007 Jun;51(6):1639-44. Epub 2007 Jan 16.

PMID:
17240038
40.

Laparoscopic-assisted nephroureterectomy after radical cystectomy for transitional cell carcinoma.

Romero FR, Muntener M, Permpongkosol S, Kavoussi LR, Jarrett TW.

Int Braz J Urol. 2006 Nov-Dec;32(6):631-8; discussion 638-9.

41.

Magnetic resonance imaging compatible robotic system for fully automated brachytherapy seed placement.

Muntener M, Patriciu A, Petrisor D, Mazilu D, Bagga H, Kavoussi L, Cleary K, Stoianovici D.

Urology. 2006 Dec;68(6):1313-7.

42.

Pure laparoscopic radical nephrectomy with level II vena caval thrombectomy.

Romero FR, Muntener M, Bagga HS, Brito FA, Sulman A, Jarrett TW.

Urology. 2006 Nov;68(5):1112-4. Epub 2006 Nov 7.

PMID:
17095065
43.

Transmesenteric laparoscopic pyeloplasty.

Romero FR, Wagner AA, Trapp C, Permpongkosol S, Muntener M, Link RE, Kavoussi LR.

J Urol. 2006 Dec;176(6 Pt 1):2526-9.

PMID:
17085149
44.

Robotic prostate surgery.

Muntener M, Ursu D, Patriciu A, Petrisor D, Stoianovici D.

Expert Rev Med Devices. 2006 Sep;3(5):575-84. Review.

PMID:
17064243
45.
46.

Refining the laparoscopic retroperitoneal lymph node dissection for testicular cancer.

Romero FR, Wagner A, Brito FA, Muntener M, Lima GC, Kavoussi LR.

Int Braz J Urol. 2006 Mar-Apr;32(2):196-201.

47.

Hemothorax after percutaneous cryoablation of the kidney.

Romero FR, Muntener M, Sulman A, Brito FA, Kavoussi LR.

Eur Urol. 2007 Mar;51(3):841-3. Epub 2006 Mar 29.

PMID:
16644093
48.

Systemic nitric oxide augmentation leads to a rapid decrease of the bladder outlet resistance in healthy men.

Müntener M, Schurch B, Wefer B, Reitz A.

Eur Urol. 2006 Jul;50(1):112-7; discussion 117-8. Epub 2006 Mar 6.

PMID:
16530931
49.

Systemic augmentation of nitric oxide: is there an immediate effect on the urinary flow rate in healthy men?

Müntener M, Reitz A, Wefer B, Schurch B.

Urol Int. 2006;76(1):31-5.

PMID:
16401918
50.

Human osseous intervertebral foramen width.

Rühli FJ, Müntener M, Henneberg M.

Am J Phys Anthropol. 2006 Feb;129(2):177-88.

PMID:
16323199

Supplemental Content

Loading ...
Support Center